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Summary: Plasma oxalic aeid concentrations were measured in 13 chronic haemodialysis patients. The mean
plasma oxalic acid concentration was 128.0 ± 48.6 μπιοΐ/ΐ, being approximately 8 times higher than the
plasma concentration of 14 volunteers (x = 16.8 ±5.2 μηιοΐ/ΐ). Ultrafiltrates obtained in vivo from these
patients showed a mean oxalic acid concentration of 138.2 ± 56.5 μιηοΐ/ΐ. Since in vivo ultrafiltrates are free
of erythrocytes and plasma enzymes, an in vitro synthesis of oxalic acid from precursors by erythrocytes and
plasma enzymes can be excluded. As the oxalic acid concentration of plasma corresponded to that of in vivo
ultrafiltrates, it is concluded that any in vitro formation of oxalic acid in haemodialysis patients must be
negligibly small, and is irrelevant for the measurement of plasma oxalic acid levels in patients receiving regul r
haemodialysis.
In vitro-Synthese von Oxals ure ist ohne Bedeutung f r die Bestimmung von Oxals ure im Plasma
bei H modialysepatienten
Zusammenfassung: Bei 13 chronischen H modialysepatienten wurde die Konzentration von Oxals ure im
Plasma bestimmt. Die mittlere Oxals urekonzentration im Plasma lag bei 128,0 ± 48,6 μπιοΐ/ΐ und war damit
etwa 8 mal h her als der Wert, der bei 14 Referenzpersonen gemessen wurde (x = 16,8 ± 5,2 μιηοΐ/ΐ).
Ultrafiltrate, die in vivo von diesen Dialysepatienten gewonnen worden waren, wiesen eine mittlere Oxals u-
rekonzentration von 138,2 ± 56,5 μπιοΐ/ϊ auf. Da in in vivo-UItrafiltraten Erythrocyten und Plasmaenzyme
nicht enthalten sind, kann eine in vitro-Synthese von Oxals ure durch Erythrocyten und Plasmaenzyme aus
Vorstufen ausgeschlossen werden. Durch den Nachweis ann hernd gleich hoher Oxals urekonzentrationen in
Plasma und Ultrafiltraten kann angenommen werden, da eine in vitro-Synthese von Oxals ure bei H mo-
dialysepatienten vernachl ssigbar klein und unbedeutend f r die Bestimmung der Konzentration von Oxal-
s ure im Plasma bei Dialysep tienten ist.
Introduction
Increased plasma oxalic acid concentrations have
been described in patients undergoing chronic hae-
modialysis (l, 2, 3). However the normal r nge of
plasma oxalic acid is still a matter of dispute. Using
chemical, fluorometric or enzymic methods the nor*
mal r nge of plasma oxalic acid is about 10—20
μπιοΐ/ΐ, being approximately 10 times higher than
the concentration obtained by human in vivo isotop-
ic investigations (r nge of plasma oxalic acid 1—3
μιηοΐ/ΐ (4—7)). This discrepancy was recently re-
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solved by Akcay & Rose, who demonstrated that
oxalic acid is synthesized from precursors in vitro by
erythrocytes when samples are allowed to stand, thus
resulting in erroneously high plasma levels in nor-
mals (8). An accumulation in the plasma of precur-
sors of oxalic acid can be expected in uraemia. The
question therefore arises of whether the increased
values found in haemodialysis are due to a genuine
physiological increase of oxalic acid, or to an in-
creased conversion of accumulated precursors by
erythrocytes and plasma enzymes in vitro. Ultrafil-
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tration before the haemodialysis, using dialysis ma-
chines adapted for Ultrafiltration, offers the oppor-
tunity to obtain ultrafiltrates free of erythrocytes and
enzymes in vivo. Oxalic acid has a low molecular
weight (Mr = 90) and shows negligible protein bind-
ing; it therefore passes freely across the dialysis
membrane, so that its concentration in the ultrafil-
trate reflects its plasma level. In the present study
pxalic acid concentrations were compared in in-vivo
ultrafiltrates and in contemporaneous plasma sam-
ples of 13 patients undergoing chronic haemodialy-
sis.
Materials and Methods
Ultrafiltrates were obtained in vivo from 13 chronic haemodialy-
sis patients by 10 minutes Ultrafiltration before the beginning of
the haemodialysis Session, s described by Schmidt and coworkers
(9). No patient suffered from primary hyperoxalaemia. Capillary
kidneys (ASAHI AM, 20) were used for Ultrafiltration. The trans-
membrane pressure was 300 mm Hg. Blood samples were drawn
simultaneously and centrifuged within l hour (fig. 1). Former stu-
dies showed that ultrafiltrate concentrations of low molecular
weight substances like creatinine and potassium correspond to
plasma levels after 10 minutes ultrafiltration (creatinine r = 0.88,
potassium r = 0.92) (9). The behaviour of oxalic acid can be ex-
pected to be similar to that of creatinine s the molecular weights
of these two substances differ only moderately (Mr creatinine 113,
oxalic acid 90) and since protein binding of oxalic acid is minimal.
Oxalic acid determinations were performed according to the pho-
tometric method described by Krugers Dagneaux et al. (4). Since
plasma proteins can influence the accuracy of the oxalic acid de-
termination, ultrafiltrates of the plasma samples were used. Ultra-
filtration of diluted plasma samples (1:10) was performed using









The mean plasma oxalic acid concentration of the 13
chronic haemodialysis patients under investigation
was 128.0 ± 48.6 μπιοΐ/ΐ, being approximately 8
times higher than the mean plasma xjxalic acid level
of 14 normal volunteers (x = 16.8 ± 5.2 μπιο1/1).
The mean oxalic acid level in the ifi-vivo ultrafil-
trates of these patients was 138.2 ± 56.5 μηαοΐΛ
Thus plasma oxalic acid concentrations were 8.7 per
cent lower than the mean oxalic acid concentration
measured in the in-vivo ultrafiltrates (Studenfs t-test
f r paired samples: t = 2.26, p < 0.05). The lower
mean oxalic acid level in plasma compared with that
of the in-vivo ultrafiltrates is probably due to small
losses of oxalic acid during the plasma determination
procedure. The correlation between the oxalic acid
levels in plasma and in the in-vivo ultrafiltrates was
highly significant (r = 0.96, p < 0.001) (fig. 2).
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Fig. K Model of ultrafiltration procedure in vivo.
T T T Transmembrane pressure (300 mmHg)
[ j Points for drawing blood or ultrafiltrate
Ultrafiltrates obtained in this way and in-vivo ultrafiltrates were
used for oxalic acid determination.
Since protein binding of oxalic acid is minimal, concentrations in
in-vivo and in-vitro ultrafiltrates can be assumed to be equal to
plasma levels.
Discussion
The mean plasma oxalic acid concentration in chron-
ic haemodialysis patients was about 8 times higher
than that in normal volunteefs. The mean oxalic acid
level in plasma was not higher than the mean oxalic
acidoconcentration of in-vivo ultrafiltrates. Further-
more oxalic acid concentrations ιη* plasma and in
plasma ultrafiltrates showed a highly significant cor-
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relation. Since an in vitro synthesis of oxalic acid can
be excluded in in-vivo ultrafütrate, we assume that
spontaneous generation of oxalic acid in blood sam-
ples is of negligible significance in the determination
of plasma oxalic acid levels in uraemic patients.
However, our results do not necessarily disprove the
relevance of in vitro synthesis of oxalic acid for the
measurement of plasma oxalic acid concentrations in
normals. It was suggested that the estimated normal
ränge for plasma oxalic acid is erroneously high, ow-
ing to the in vitro conversion of glyoxylic acid (a pre-
cursor) to oxalic acid by erythrocytes in blood sam-
ples on Standing (8). Akcay & Rose showed that gly-
oxylic acid added to blood samples is converted to
oxalic acid immediately by erythrocytes (8). Rehmert
and coworkers demonstrated the in-vitro synthesis
of oxalic acid in plasma of normals. The formation of
oxalic acid could be prevented by addition of enzyme
inhibitors (3). In addition to glyoxylic acid, other
precursors, like glycolic acid, ascorbic acid or gly-
cine, could contribute to in vitro synthesis of oxalic
acid (10).. In uraemia, the accumulation of these
compounds, resulting in elevated plasma levels, can
be expected or has even been proved. Therefore an
increased in vitro formation of oxalic acid from pre-
cursors might be expected in uraemia. Our results,
however, demonstrate that the in vitro conversion of
these precursors could make only a negligibly small
contribution to the elevated plasma oxalic acid con-
centrations in uraemic patients. In fact, such a con-
version cannot be demonstrated by the method used.
It can therefore be assumed that the increased plas-
ma oxalic acid concentrations measured in uraemia
genuinely reflect the accumulation of oxalic acid in
renal failure.
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